Another issue that exists within allogeneic cell therapy development is the donor ... licensed clinical manufacturing facility, located near Glasgow, UK, to remain ‘vertically integrated’.
In the world of cell therapy, Silicon Valley has long recognized that technological innovation is the key to solving ...
Shelf, Allogeneic CD7-Targeted CAR-T Cell Therapy to Begin in First Quarter 2025 ...
About P-CD19CD20-ALLO1 P-CD19CD20-ALLO1 is an allogeneic CAR-T cell therapy product candidate ... Inc. We sell different types of products and services to both investment professionals and ...
We explore the immense potential of gamma delta T cells, and the challenges in sourcing and scaling up sufficient volumes to ...
BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can ...
TrakCel, a provider of integrated cell and gene therapy (CGT) orchestration solutions for the precise management, control and tracking of CGTs has today announced that its orchestration platform ...
NK cells, as opposed to T cells, do not induce graft-versus-host disease (GVHD), therefore treatment-related toxicity owing to allogeneic donor NK cell administration is minimal. Alloreactive NK ...
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
Competition in the cell therapy space is substantial, especially given the progress of one competitor, Fate Therapeutics (FATE). FATE is developing an allogeneic CAR-NK cell targeting CD-19 called ...
Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that ...
FDA approves Autolus Therapeutics' Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback